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For the first time, we reveal a direct interaction between Rap1b and the fly 
homolog of talin, Rhea. Using a combination of biochemical and biophysical 
techniques, the Rap1 binding site on Rhea has been successfully mapped. 
Additionally, we reveal that an acidic-to-basic K17E substitution, on Rhea, 
completely abolishes Rap1 binding. Our collaborators have shown that this 
mutation results in non-viable embryos and our data links the Rap1:Rhea 
interaction to this lethal phenotype. The implications of our findings support 
currently proposed mechanisms of RIAM-independent integrin activation, that 
would challenge our understanding of focal adhesion formation. Furthermore, we 
propose a double-dependent Rap1 integrin-activation pathway, involving Rap1 
directly interacting with the FERM domain, alongside the known Rap1-dependent 
recruitment of talin.  
Optimisations have allowed us to express both the wild-type and mutant Rhea F0 
domain in E.coli BL21(DE3) cells. Efficient purification via Ni-NTA-based affinity 
chromatography results in yields of ~50-60 mg/litre being obtained.  Using circular 
dichroism, it is shown that substitution of the K17 residue does not interfere with 
the structural integrity of Rhea; both proteins have identical full spectrum 
measurements and Tm values. 
Optimal expression of the conserved G-domain of mouse Rap1b was achieved in 
the CK600K cell line. This region is highly conserved to that in fly (90% identical). 
NMR was used to show direct interaction between drosophila Rhea F0 and Rap1b; 
whilst additionally confirming that Rap1b was unable to induce chemical shifts in 
the F0-K17E mutant. Triple resonance NMR experiments revealed the location of 
the Rap1 binding site on the wild-type Rhea F0, with V15, K17, T18, K37 and E40 
being highlighted at the centre of this interaction. Structural models of Rap1:Rhea 
F0 binding agree with our findings, with the 5 highlighted residues seen to make 
close contact with the Rap1 switch I domain. 
Together this work confirms a direct interaction between Rhea and Rap1 whilst 
providing biochemical validation for the lethal phenotypes observed in mutant 
flies. It also provides further insight into new mechanisms of focal adhesion 
formation and integrin activation. 
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The N-terminal contains an F0 domain which is atypical of FERM domains. The FERM 
domain also contains the F1, F2 and F3 domains, typical of FERM domains. F3 contains a 
phosphotyrosine binding-like domain. This site binds to the cytoplasmic tails of Š-
integrins. Proceeding the FERM domain, and an unstructured linker region, is the Talin 
Rod domain. This comprises of thirteen helical bundles, each containing 4 or 5 helixes. 
F0 contains a Rap1 binding site.RIAM binds to the talin R2/R3 subunits of the rod domain 
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The content of the following section, on the basic principles of NMR, is from a 
series of video tutorials produced by Magritek Ltd and delivered by Sir Paul 
Callaghan. All information from this section will be assumed to have come from 
this source, unless cited otherwise. The following description of NMR will avoid 
the quantum mechanics necessary for a deep understanding of NMR, in an attempt 
to keep the understanding at a level that is more appropriate to those with little 
Biophysical background. 
Understanding NMR requires a basic knowledge of how atomic nuclei behave in an 
applied magnetic field (B0). A key property of nuclei, that allows us to study them 
via NMR, is magnetism. This property results in the magnetic dipole of the nuclei 
aligning with a magnetic field when placed in it. The further key properties of 
atomic nuclei that aid this understanding, are angular momentum (spin) and the 
fact that, in the case of 1H, 13C and 15N, the nuclei can exist in one of two 
orientations 1HU]6WRUPHV, or quantum states (see )LJXUHA). The first 
is known as ´XSVSLQµLQZKLFKWKHRULHQWDWLRQLVDOLJQHGZLWKWKHPDJQHWLFILHOG
which is the lowest energy state for the nuclei to reside. The second orientation 
LV´GRZQVSLQµZKLFKLVDOLJQHGDJDLQVWWKHPDJQHWLFILHOGWKHUHIRUHRFFXS\LQJ
a higher energy level. In order to disrupt the nuclei from their natural orientation, 
ILUVWO\D´WRUTXHµDVHFRQGHOHFWURPDJQHWLFILHOGPXVWEHDSSOLHGDVDSXOVH
RUWKRJRQDOO\WRWKHPDJQHWLFILHOG6HFRQGO\WKH´WRUTXHµPXVWRVFLOODWHYDU\LQJ
with time) at the same frequency (resonance) as the precession frequency of the 
nuclear spin. When nuclei are at 90° to the magnetic field, they will precess, 
rotating around the axis of the magnetic field, and undergo relaxation until they 
re-orientate back along the axis of the magnetic field (see )LJXUHE). With time, 
as the nuclei re-orientate themselves, the precession decreases until the angular 
momentum is back at equilibrium. We can say that precession is dependent on the 
orientation of the nuclei; it is not observed when the nuclei are in either of their 
two natural states. Precession frequency is the time it takes for the nuclei to 
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precess a single time, and remains constant at all orientations aside from in the 
up or down spin states.  
The Boltzmann factor defines the proportion of atomic nuclei in the higher and 
lower energy quantum states and is defined by the proportion of magnetic energy 
to thermal energy 5DWWOH. The proportion of atomic nuclei occupying the 
lower energy orientation will increase as either the temperature decreases, or the 
magnetic energy increases. At absolute zero all spins will be in the low energy 
orientation, however, at room temperature, thermal energy becomes a factor in 
the Boltzmann distribution, and there is a distribution of atomic nuclei in each 
state; the thermal energy will allow the atomic nuclei to occupy the down spin 
orientation. As expected however, there will be a slight preference for the lower 
energy state, so there will be slightly more atomic nuclei occupying this quantum 
state (see )LJXUHC). 7KLVLPEDODQFHLQWKHSRSXODWLRQVLVFDOOHGD´ VSLQH[FHVVµ
At room temperature, the Boltzmann distribution states that we will have a near 
equal number of atomic nuclei in each state. The populations occupying the up 
and down spins will cancel each other out and are not seen. The spin excess 
however, is visible. This is due to the fact that the low proportion in the spin 
excess still equates to a very large number of actual atomic nuclei in a given 
sample. The Boltzmann population allows us to predict two ways of increasing the 
spin excess. Firstly, we could perform the NMR experiments at a lower 









DJDLQVW ´GRZQµ VSLQ WKH PDJQHWLF ILHOG & DOLJQLQJ ZLWK WKH PDJQHWLF ILHOG LV WKH
ORZHVW HQHUJ\ VWDWH DOLJQLQJ DJDLQVW LW UHTXLUHV HQHUJ\$W DEVROXWH ]HUR WKH HQWLUH
SRSXODWLRQLVLQWKHXSVSLQRULHQWDWLRQ$WURRPWHPSHUDWXUHWKHUPDOHQHUJ\LVSUHVHQW
DOORZLQJ WKH QXFOHL WR EH LQ HLWKHU RULHQWDWLRQ 7KHUH LV D VPDOO WHQGHQF\ IRU WKH
SRSXODWLRQ WR KDYH VOLJKWO\ PRUH QXFOHL LQ WKH ORZHU HQHUJ\ VWDWH RUDQJH ZKLFK LV
FDOOHGWKHVSLQH[FHVV7KHVSLQH[FHVVLVREVHUYHGLQ105DVVLJQDOVIURPWKHXSDQG
GRZQVSLQQXFOHLFDQFHORXW'ILULQJDQRVFLOODWLQJSXOVHDWLQUHVRQDQFHZLWKWKH
/DUPRU IUHTXHQF\RI WKHQXFOHLZLOOGLVUXSW WKHRULHQWDWLRQRIWKH VSLQ VR WKDW( WKH
QXFOHL EHJLQ WR SUHFHVV 7KLV SUHFHVVLRQ LQGXFHV DQ RVFLOODWLQJ YROWDJH LQ WKH 105
GHWHFWRUFRLOZKLFKIDGHVDVWKHQXFOHLUHWXUQWRWKHLURULJLQDORULHQWDWLRQ 
 
The precession of an atomic nucleus is known as Larmor precession; which takes 
place at the Larmor Frequency. This frequency is directly proportional to the 
magnetic field (B0); a larger B0 will increase the precession frequency (the Larmor 
Frequency is defined as Ŵ= Š%0 where gamma is the gyromagnetic ratio 
(dependent on the nature of each atomic nucleus)). The last feature of the 1D 
105 H[SHULPHQW LV WKH FRLO 7KLV LV UHVSRQVLEOH IRU SURGXFLQJ WKH ´WRUTXHµ D
transverse, oscillating magnetic field at the same frequency as the Larmor 
Frequency of the atomic nuclei, applied as a pulse. Not only does this coil produce 
the oscillating magnetic field, it also serves as a detector. As the nuclei precess, 
their fluctuating magnetic fields produce an oscillating voltage in the coil, which 
corresponds to its precession. This signal decays over time, as the precession 
returns to its equilibration state, and is known as Free Induction Decay (FID). The 
FID is a collection of the Larmor frequencies of all of the protons in a unique 
chemical environment within the sample. Each of these will therefore be decaying 
at different rates. A FID can be converted via Fourier transform, from a function 
of time, to a function of frequency, thereby giving us the 1D NMR spectrum see 
)LJXUH) (5DWWOH. 
Due to shielding from electrons, different hydrogen environments correspond to 






)LJXUH7KHGLIIHUHQWUHJLRQVRIDW\SLFDO105VSHFWUXP(Albert Einstein College of 
Medicine, 2012) 
 











)LJXUH $ 7KH QDWXUDOO\ RFFXUULQJ LVRWRSH RI QLWURJHQ QLWURJHQ LV QRW





RQO\VRXUFHRIQLWURJHQ LQWKHPHGLD LWZLOODOVREH LQFRUSRUDWHG LQWRWKHVLGH

















GLPHQVLRQ WR WKH VSHFWUD DQG FRXSOH WKH DPLGH WR DGMRLQLQJ FDUERQV 7ULSOH
UHVRQDQFH105DOORZVWKHDVVLJQPHQWRIWKHVSHFWUDLGHQWLI\LQJWKHH[DFWDPLQR
DFLG WKDW HDFK SHDN FRUUHVSRQGV WR WKXV DOORZLQJ IRU PRUH PHDQLQJIXO













:HKDYH WRFRQVLGHUD IUDPHRI UHIHUHQFH IRU WKHEDFNERQH DQG WKH FRPPRQ
QRPHQFODWXUH GHVLJQDWHV WKH DPLQR DFLG ZH DUH ORRNLQJ DW DV ´Lµ ZLWK WKH
SUHFHGLQJDPLQRDFLGLQWKH1WHUPLQDOGLUHFWLRQDV´LµDQG´LµEHLQJWKH



















1.6 Project aims: 
 
The aim of this study is to produce work that can contribute towards a 
collaborative paper between Dr Goult and Dr Tanentzapf, at the University of 
British Columbia, Vancouver. This paper will take a multidisciplinary approach to 
understanding a new interaction between Rap1 and Rhea/Talin. Dr Tanentzapf 
uses CRISPR to insert mutations into endogenous genes and then images and 
studies observed phenotypes in drosophila embryos. Alongside this, the Goult lab 
use biochemical and biophysical techniques to understand the biochemistry that 
underpins these protein interactions. A successful collaboration of this nature was 
performed previously in their paper on talin autoinhibition (Ellis et al., 2013), 
where studies were performed that produced talin-null mutant embryos, labelled 
for integrin and F-actin. They demonstrated that the talin-null mutant could be 
rescued with talin-GFP but that recue failed with the autoinhibition defective talin 
E1777A mutant protein. Dr Goult provided the biochemistry that compared the 
WT talin and E1777A mutants, and characterised the autoinhibition process.  
 
)LJXUH7DOLQ$XWRLQKLELWLRQ0XWDQWV 
In their previous collaboration, Dr Goult and Dr Tanentzapf showed that talin-null 
embryos (B) could be rescued with talin-GFP (A) but not with the autoinhibition 
defective talin E1777A protein (C-D). The asterix in C identifies an open dorsal hole. 




The aim of this study is to produce a similar collaboration. Dr Tanentzapf has 
demonstrated that the Rhea F0-K17E mutation is embryonic lethal (unpublished). 
Dr Goult has identified a new interaction between talin F0 and Rap1 (Goult et al., 
2010) whilst showing that the equivalent mouse talin F0-K15E mutation perturbs 
Rap1 binding (unpublished). We therefore want to demonstrate that these 
interactions are also occurring in drosophila, to link this interaction to the 
observed lethal phenotypes. 
 
We have therefore set out to answer the following questions: 
 
- Does the Rhea F0-WT protein bind Rap1b? 
- Does this interaction still occur in the Rhea F0-K17E mutant, or is Rap1 binding 
perturbed? 
- Can we identify additional key Rhea F0-WT residues involved in binding to 
Rap1? 
- Can we identify the location of the Rap1 binding site on structural models of 
Rhea F0? 
- Do our findings agree with the structural models of Rhea:Rap1 binding? 
- What conclusions will the data allow to be drawn in relation to the current 













Section 2: Methods 
 
Methods 2.1: Materials and Reagents 
 
 Table 2: Materials and Reagents  
 Source Composition 
Acrylamide 
 




















Instant BlueTM stain 
 
expedeon  
Ni-NTA Buffer A 
 
 20 mM Tris, 500 mM NaCl, 
20 mM Imidazole, /L, pH8 
Ni-NTA Buffer B 
 
 20 mM Tris, 500 mM NaCl, 
500 mM Imidazole, /L, 
pH8 
Ni-NTA Buffer B (Batch)   20 mM Tris, 500 mM NaCl, 




Q buffer A  
 
 20 mM Tris, 50 mM NaCl, 
2 mM DTT, /L, pH8 
Q buffer B  
 
 20 mM Tris, 1000 mM 
NaCl, 2 mM DTT, /L, pH8 
2M9 Solution A, for 15N 
labelling (per 750ml) 
 
 9.375 g Na2HPO4, 5.625 g 
KH2PO4, made to 750 ml 
and autoclaved. 
2M9 Solution B, for 15N 








SIGMA Life Science 
3.0 g Glucose, 7.5 ml Milli 
4 ¶XOWUDSXUH ZDWHU· 
ml BME vitamins, 1.5 ml 
MgSO4 (1 M), 0.075 ml 
CaCl2 (1 M), 0.75 ml 
Ampicillin (1 mg/ml 
stock), 0.75 g 15NH4Cl. 
Filter sterilised with 0.2 
OILOWHU 
2M9 Solution B, for 13C15N 




SIGMA Life Science 
Same as 2M9 Solution B, 
for 15N labelling, with the 
substitution of D-
Glucose-13C6 





Tryptone 10g/l  
Sodium Chloride 5g/l 
Yeast Extract 5g/l 
NMR phosphate buffer 
(per L) 
 
 1.9 g NaH2PO4, 0.9 g 
Na2HPO4, 2.9 g NaCl, 0.3 
g DTT, pH 6.5, made to 
1000 ml* 
HisPurTM Ni-NTA Superflow 
Agarose  
 
Thermo Scientific  
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PBS   8 g NaCl, 0.2 g KCl, 1.44 
g Na2HPO4, 0.2 g KH2PO4 
/L, pH 7.4 
Glycerol Stock (50%) Glycerol: Fisher 
Chemical 
20 ml glycerol and 20 ml 
water, filter sterilised. 
TEMED BIO-RAD  
Ammonium Persulphate Fisher Chemical   
Kanamycin sulfate  SIGMA Life Science  
CaCl2 / glycerol  
 
 
 0.1 M CaCl2, 10% glycerol: 
150 ml stock contained 
15 ml glycerol and 2.205 
g CaCl2 and 135 ml Milli-Q 
ultrapure water 
Sample Buffer   
 SnakeSkin Dialysis Tubing Thermo Scientific 10K MWCO 
 
All buffers were made with Type1 reagent-grade water from a Milli-Q Academic 
Ultrapure Water System 
 




Competent cells were in 100 µl aliquots. These were thawed on ice and divided 
into 50 µl aliquots. Immediately after thawing, 2 µl of DNA vector was added to 
each prior to gently mixing. The cells were returned to ice for a further 30 
minutes and then heat shocked at 42°C for 45 seconds. Following this, cells were 
allowed to recover for a further 2 minutes on ice. The transformed cells were 






Following the transformation, the cells were added directly to 10 ml of LB and 
antibiotic (Amp for Rhea constructs in BL21(DE3) cells / Amp + Kan for Rap1 in 
CK600K cells). The following morning, glycerol stocks were produced and 




300 µl of filter sterilised glycerol (50%) was added to 750 µl of the overnight 




A scraping of glycerol CK600K cell stock was cultured overnight in 5 ml of LB + 
Kan. The following day, 5 ml culture was added to a 500 ml flask of LB + Kan. This 
flask was incubated at 37 °C until the cells reached an OD 595 of 0.6-0.8. The cells 
were then divided into 10x 50 ml fractions and left to cool on ice for 10 minutes. 
The fractions were centrifuged at 4000 rpm for 10 minutes at 4°C a nd the 
supernatant discarded. Each pellet was resuspended in 10 ml of ice cold CaCl2 / 
glycerol and left on ice for 15 minutes, prior to a subsequent spin at 3000 rpm for 
10 minutes for 4°C. The supernatant was carefully removed and discarded . Pellets 
were resuspended in 1 ml of ice cold CaCl2 / glycerol and aliquoted into 100 ȝO
fractions. Aliquots were flash frozen in liquid nitrogen before storing at -80°C.  
 




LB was prepared at 20 g per litre and autoclaved prior to use. 
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Ampicillin stocks were at a concentration of 50 mg/ml and ampicillin at 100 




Prior to induction and harvesting, 1 ml of cells were taken from the culture, centrifuged 
for 2 minutes and the pellets were frozen at -20°C. Pre-induction pellets were 
resuspended in 500 ORI3%6 and sonicated 2x on ice for 20 seconds each, with 20 seconds 
between sonications. Sonications were done on an MSE Soniprep 150 at 14 amplitude 
microns. At the different stages of the process, samples were taken for analysis by SDS-
PAGE. 50 OZDVWDNHQDQGERLOHGZLWK ORIVDPSOHEXIIHUIRU 5 minutes at 95°C. The 
post-induction pellets were prepared in the same way. The first fraction represented 
the whole-FHOOSURWHLQFRQWHQWVRIWKHVDPSOH7KHUHPDLQLQJOZDVFHQWULIXJHGIRU
5 minutes, and 50 O ZDV WDNHQ WR UHSUHVHQW WKH VROXEOH IUDFWLRQ RI SURWHLQV 7KH
supernatant was discarded and the insoluble pellet resuspended in 450 O RI 3%6 $
further 50 OZDVWDNHQDQGERWK OIUDFWLRQVZHUHERLOHGZLWK ORIVDPSOHEXIIHU
for 5 minutes at 95°C. When analysing with SDS-PAGE, loading volumes were adjusted 




This method was used alongside the Lysis and Centrifugation Protocol (see 2.2.8), 
to determine soluble protein levels present in the 30 ml resuspended cell pellets.  
$IWHUVRQLFDWLRQORIVDPSOHZDVWDNHQDQGERLOHGZLWKORI sample 
bufferWRUHSUHVHQW´ZKROHFHOOµFRQWHQWVRIWKHSUHS)ROORZLQJcentrifugation, 
ORI VDPSOHZDV WDNHQDJDLQDQGERLOHGZLWK ORI sample buffer, to 
UHSUHVHQW WKH ´VROXEOHµ FRQWHQWV RI WKH SUHS 'XH WR WKH GLIILFXOW QDWXUH RI
resuspending an insoluble pellet of this size, the insoluble fraction was not taken 






Cultures were pooled in 1 L centrifuge pots and centrifuged at 4000 rpm for 10 
minutes. The pellets were resuspended, and aliquoted, in 30 ml of Ni-NTA-A 
buffer (if His-tagged) or Q-Buffer A (if untagged) per half litre of prep. This was 
done to allow effective sonication, by ensuring the cell density was not too high 




30ml resuspended cell pellets were defrosted in a beaker of water at room 
temperature. This freeze-thaw process was used as part of the cell lysis step 
(Johnson and Hecht, 1994). Cells were sonicated on ice with 6 cycles of 20 
seconds on, 40 seconds off. Each sonicated pellet was then centrifuged for 20 





Samples were boiled at 95°C for 5 minutes prior to SDS-PAGE analysis. Typically, 
50 ORIVDPSOHZDVERLOHGZLWK ORIVDPSOHEXIIHU (with the exception of the 
section 2.2.6.2 solubility test, where 30 O of sample was boiled with 200 O of 
sample buffer).  
Denaturing SDS-PAGE gels were run at 200V for approximately 40 minutes. Gel 
lanes  were loaded with 10 O RI VDPSOH KRZHYHU WKLV YROXPH ZDV DGMXVWHG, 
where appropriate, to account for different concentrations; such as in pre- and 
post-induction expression tests. Gels were made with a 12% separating and 4% 
stacking component, in pre-made gel FDVVHWWHVDFFRUGLQJWR1RYH[JHOFDVWLQJ








Table 3: The composition of the gels used for SDS-PAGE 
Separating Gel 12% Stacking Gel 4% 
40% acrylamide 7.5 ml 40% acrylamide 1.25 ml 
Separating Gel Buffer 9.4 ml Stacking gel buffer 4.2 ml 
10% SDS 250 O 10% SDS 125 O 
50% sucrose 4.0 ml Water 6.05 ml 
water 3.3 ml TEMED 5.0 O 





625 O   
 
Ammonium persulphate was at a concentration of 50 mg/ml. 
Separating gel buffer (1 M Tris-HCl, pH8.8): 30 g of Tris in 250 ml of water, 
adjusted to correct pH with HCl 
Stacking gel buffer (0.375 M Tris HCl, pH6.8): 11.4 g of Tris in 250 ml of water, 




In order to purify the target proteins, affinity chromatography was principally 
used; a technique that takes advantage of protein binding interactions. By tagging 
proteins with a His-tag, they have a high affinity for Ni-NTA resin, meaning they 
can be isolated from cell lysates (Alberts et al 2002). In this type of purification, 
firstly, the soluble cell lysates are passed through a Ni-NTA affinity column. The 
His-tagged proteins will bind to the column whilst the majority of un-tagged 
proteins will pass straight through. A low imidazole (20 mM) Ni-NTA buffer A is 
washed through the column to remove as much non-specific binding as possible. 
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Then a gradient of increasing imidazole concentration is run (up to 500 mM in 
these experiments) and the eluted fractions are collected. At a specific 
concentration of imidazole, the His-tagged proteins are eluted from the column 
and in the process are purified and concentrated. Non-specifically bound 
impurities are likely separated, from the target protein, by eluting at different 






Protein was loaded onto a desalting column and exchanged into Q-Buffer A using 




The pd10 column was washed with 25 ml of phosphate buffer, then 2.5 ml of 
protein was added to the column. The protein was then eluted with 3.5 ml 
phosphate buffer. This was repeated as required dependent on the volume of 
protein. Any remaining protein was made up to 2.5 ml with phosphate buffer and 




To exchange from Q-Buffer A to phosphate (NMR) buffer, proteins were dialysed 




In order to get the proteins above 90% purity, and suitable for biochemical assays, 
a subsequent purification step via ion-exchange chromatography was used after 
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Ni-NTA chromatography. Proteins were exchanged into Q-Buffer A and run 
through an anion exchange Mono-Q column.  The column is positively charged 
and therefore, negatively charged proteins stick to the column and can be eluted 
with a salt gradient. When proteins are in a buffer with a pH greater than their 
pI, they have a net negative charge, as basic groups of the protein tend to be 
uncharged, while negative charges arise from carboxylic acid groups (Albert et 





ORI1L-NTA Resin was cleaned, in Q-Buffer A (same buffer as the proteins 
were in), and then added to the protein. The sample was agitated gently for 15 
minutes to allow binding to the resin to occur. This removed any uncleaved 
protein, cleaved His-tags and TEV from the solution. To remove the resin, and any 
precipitate, the sample was then filter sterilised with a sterile 0.2-micron filter. 
SDS-PAGE analysis was then used to determine to protein purity.  
 




For the initial expression trial, overnights of BL21(DE3) cells transformed with 
pet151-TOPO DNA vectors containing either F0-WT or F0-K17E were put on. These 
overnights were cultured in autoclaved, bevelled flasks containing 750 ml of LB 
+ Amp. The volumes of each overnight culture added were adjusted according to 
their respective OD595. This ensured that the cultures would be at the same 
starting density at time 0. The cultures were incubated and shaken at 37°C for 
around 4 hours, until the OD595 reached 0.5. The cells were induced for 3 hours 
with 0.25 mM IPTG. The cells were harvested prior to a solubility test being 






Further cultures were grown of F0-WT and F0-K17E, as before, but upon reaching 
the correct OD, the flasks were then taken out of the incubator, and placed into 
room temperature water to cool2QFHFRROWKHIODVNVZHUHLQGXFHGZLWK0
IPTG and incubated with shaken overnight at 18°C. Cells were harvested (see 




Cells pellets were lysed and centrifuged (see 2.2.8), and the soluble fractions 
were purified using Ni-NTA FPLC (see 2.2.10). The main A280 peaks for each 
protein corresponded to fractions A11-A15, with a second peak arising between 
B15-B14. These fractions were analysed with SDS-PAGE prior to pooling the A12-
A15 fractions for F0-WT and the A11-A15 fractions for Rhea F0-WT and F0-K17E. 
The protein was desalted into Q-Buffer A (see 2.2.11.1) and cleaved overnight 
with TEV (a cysteine protease that cleaves between the Q\S of the ENLYFQ\S 
sequence that links the His-tag to the protein) at 4°C. The following day, the 
prep was cloudy, indicating a large amount of precipitation. A fraction was taken 
and then the sample was spun for two minutes, and transferred to a clean falcon 
tube, to separate it from the precipitate. The sample was purified via ion 
exchange chromatography (section 2.2.12). The F0-WT and F0-K17E proteins 
were present in the flowthrough; the proteins bound very weakly to the column, 
but were washed out with the low salt buffer. To check that the TEV cleavage 
had been successful in removing the His-tag, uncleaved and cleaved fractions 
were analysed by SDS-PAGE. The flowthroughs were aliquoted into 1 ml fractions, 




Isotopic labelling was performed by culturing in 2M9 minimal media. 2x 750 ml 
flasks of 2M9 solution A were prepared and autoclaved in bevelled flasks. The 
2M9 solution B is not able to be autoclaved and so was prepared and filter 
  
44 
sterilised into 2x falcon tubes. Prior to growth the 2M9 solution B was added to 
the 2M9 solution A to produce 2M9 minimal media. 
In order for the cells to become acclimatised to minimal media, overnight 
cultures were grown in 2M9. A scraping of the glycerol stocks of F0-WT and F0-
K17E was cultured overnight with 10 ml 2M9 solution A and 270 ORI0VROXWLRQ
B. The following morning, after successful growth, fresh glycerol stocks were 
made of these cells, for use with future preps in minimal media. Adjusted 
volumes of overnight culture were added to each flask, which were then grown 
up and purified as described in section 2.3.1.3. A notable difference is that 




Double labelled Rhea F0-WT was produced using the same conditions as described 
in 2.3.1.4, aside from the use of isotopically labelled, D-Glucose-13C6. Additional 
TEV was required to obtain complete cleavage prior to Q-Column Purification, 
and this was achieved by adding more TEV at room temperature for 40 minutes. 
Subsequently, cleaved His-tags and uncleaved protein were removed (see 
2.2.13). The protein was put in a 3,000 Da concentrator and spun for 2x 20 
minutes at 4000 rpm and concentrated down to 1 ml, where the concentration 
was measured at 5 mg/ml. 
The 1 ml of concentrated protein was split; OZDVXVHGLPPHGLDWHO\IRU105
DQDO\VLVDQGWKHRWKHUOZDVIODVKIUR]HQDQGVWRUHGDW-20°C. 
 









ZLGWK DFFXPXODWLRQ RI  DQG UDQ IURP  QP$OO PHDVXUHPHQWV ZHUH
SHUIRUPHGRQD-DVFR-DQGFRQYHUWHGWR0HDQ5HVLGXH(OOLSWLFLW\DVGHVFULEHG






ZLWK D GDWD SLWFK RI & GHOD\ WLPH RI  VHFRQGV DQG WHPSHUDWXUH VORSH RI
&PLQXWH 
 




All NMR experiments were performed on a Bruker 600 MHz spectrometer 
equipped with CryoProbe. To prepare samples for NMR analysis, 25 µl of D20 
was added to 425 µl of 15N labelled sample to yield a 450 µl sample suitable for 
NMR. Rhea F0-WT was at 0.90 mg/ml and F0-K17E at 1.10 mg/ml. Experiments 
were done at 298 K, at pH 6.5.  
 




13C15N Rhea F0-WT was at 5.0 mg/ml. 25 µl of D20 was added to 425 µl of 
double labelled sample to yield a 450 µl sample suitable for NMR. HNCO, HNCA, 
HN(CO)CACB, HNCACB and HN(CO)CA triple resonance experiments were 
performed. Experiments were done at 298.0 K, at pH 6.5. The experiments 






The information from this section comes from a series of lecture notes, for a 
JUDGXDWH 105 FRXUVH HQWLWOHG ´7ULSOH UHVRQDQFH H[SHULPHQWV DQG VWUXFWXUH
GHWHUPLQDWLRQµIURP0DUN*LUYLQDQG6HDQ&DKLOODWWKH$OEHUW(LQVWHLQ&ROOHJH
of Medicine, NY, 2012 who cite the following authors: Cavanagh, J. (2007). 
Protein NMR spectroscopy. Amsterdam: Academic Press. Evans, J. (1995). 
Biomolecular NMR spectroscopy. Oxford: Oxford University Press. Additional 
information comes from Goult et al., 2015 
As explained in the introduction, 3D NMR involves coupling spins, so that 
magnetization transfer occurs between different atomic species within the 
protein backbone. For the assignment in this study, 5 experiments were carried 
out to allow peaks to be observed for different carbons at i and i-1.  
Note that the FDUERQ\OLVW\SLFDOO\UHIHUUHGWRDV´ &2µWKHDOSKDFDUERQDV´ &$µ
DQGWKHEHWDFDUERQDV´&%µZKLFKLVWKHILUVWFDUERQRIWKHVLGHFKDLQSUHVHQW
on all amino acids aside from glycine).  
The first experiment was the HNCO (Figure 15A). In this experiment, the 
magnetization was transferred from the amide proton to the nitrogen. From 
there, it was transferred to the carbon of the carbonyl of the preceding residue, 
i-1. From CO, the magnetization was passed back to the nitrogen, and then 
hydrogen, for acquisition. Having performed a HNCO we observe a single peak 






The next experiment was the HNCA (Figure 15B). The magnetization was 
transferred from the proton to the nitrogen again, but this time it principally 
transferred to the CA at i. We therefore see a peak for this CA. We also observe 
a peak for the CA-1, as the magnetization skips across the i-1 CO. Usually this 
peak is smaller than for the CA. 
The HN(CO)CACB was one of the most important experiments, in that it 
transferred the magnetization from the proton, to the nitrogen, skipping across 
the CO, to the CA-1 and CB-1. We therefore observe peaks for the CA-1 and CB-




The next triple resonance experiment performed was the HNCACB. After 
transferring from the hydrogen to the nitrogen (Figure 16D), the magnetization 
passed to the CA and CB at i. We therefore observe peaks for these. We also see 
peaks, for the CA-1 and CB-1, as the magnetization skips over the CO and passes 
to these two carbons. This experiment therefore results in four observable 







The final experiment used for the assignment was the HN(CO)CA, where the 




The HNCACB tells us the chemical shifts for the CA, CB, CA-1 and CB-1. For each 
residue, their CA and CB values lie at defined chemical shift values (see Figure 
19) This means that from the HNCACB, we can predict which amino acid we are 
looking at from the CA and CB at i, and which it is next to, from the CA-1 and 
CB-1. We simply need to work out which of the 4 peaks are which, and to do this, 
we use the other triple resonance experiments, which can be overlaid using the 
CCPNMR Analysis software. In order to determine which 2 peaks belong to i, and 
which belong to i-1, the HN(CO)CACB can be overlaid with the HNCACB, which 
will mark the CA-1 and CB-1. The HNCA can then be overlaid to determine which 
2 of the 4 peaks are the alpha carbons. This means that we can differentiate the 





As seen in Figure 18, looking from right to left, we first see the four peaks in the 
HNCACB. Toggling on the HNCA allows us to determine that the two middle peaks 
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of the HNCACB are alphas. The HN(CO)CACB tells us that the top peak of the 
HNCACB must be the CB-1, whereas the next peak is the CA-1. This reveals the 
third peak down to be the CA own (at i), leaving the bottom peak to be the CB 
own. The HN(CO)CA can be used as a toggle to quickly determine which peak is 
the CA-1 when looking at the HN(CO)CACB.  
 
When we look at the chemical shift values of each peak, the CA at i is at 60 ppm, 
and the CB at i is at 70 ppm. This tells us that we are most likely observing a 
threonine (Figure 19) which is a diagnostic residue for backbone assignment. This 
is due to the fact that there are only two residues with a beta chemical shift 
higher than an alpha chemical shift. The chemical shifts of the CA-1 and CB-1 tell 






system that has a corresponding, identical chemical shift for its own alpha and 
beta, as that of the alpha and beta minus one of the threonine. We see this 
corresponding spin system in Figure 20, in the second row from the left (the 
threonine at i+1, to the right). For the i-1 amino acid, it only has one peak for its 
own i-1 (i-2 for the threonine), which can be confirmed to be a CA-1 using the 
HN(CO)CA. There is only one amino acid without a beta carbon, meaning that the 
downstream amino acid must be a glycine. If we then look at the entire sequence 
of amino acids for the Rhea F0, we can try to identify G-R-T. In this example, it 
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turns out that this combination is unique, only occurring once in the sequence. 




This can be confirmed when looking for the i-3 residue of the 69T. In the 
sequence, this should be a proline. Proline, does not have an amide and therefore 
does not have its own spin system that can be observed at i, however they can 
always be seen at the i-1 of its upstream amino acid. Looking at the chemical 
shift of the i-3, we see values that are diagnostic of a proline, and these CA-1 
and CB-1 have no matching beta and alpha own, when looking at all the other 
spin systems. 
The way that this is carried out in CCPNMR, is by propagating the peaks of the 
CA-1 and CB-1 to the HN(CO)CACB strips, and the CA and CB owns to the HNCACB 
strips. Under the assignment options of the program, you can then set the 
HN(CO)CACB as a query, and the HNCACB as a match. This means that when you 
click on the strips for a given peak, it will automatically highlight the CA-1 and 
CB-1, and search through every other strip, to look for amino acids that have 
similar chemical shifts for their CA and CB RZQV,QWKLVZD\\RXFDQ´ZDONµ\RXU
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way down the protein backbone, matching up neighbouring amino acids, until 
you find diagnostic regions that tell you where in the sequence you are observing. 
When selecting the peaks from the HSQC, it can be noted that there are peaks 
which are not from the protein backbone. These can easily be distinguished as 
side chain amino acids, as they have no proper spin systems, when navigated in 
HNCACB. 
Having completed the assignment, the chemical shifts were used to calculate 
the dihedral angles based on chemical shift indexing with the program DANGLE 
which forms part of the CCPNMR package. This created a Ramachandran Plot 
output and determined the secondary structure elements of the F0 domain 
(Figure 36 left).  
 




Rap1-His and -untagged constructs were transformed into E.coli BL21(DE3) cells 
as described previously. 1RWHWKDW´5DSµZKHQPHQWLRQHGLQWKHFRQWH[WRIWKH
'URVRSKLODIRUPLVUHIHUULQJWR´ 5DV-OLNHSURWHLQµEXWZLOOEHQDPHGDV´ 5DSµ
from here onwards. The constructs were already prepared previously by the 
Goult Lab. Overnight cultures were grown in LB + Amp, and subsequently 
transferred to 750 ml flasks of LB + Amp as described in section 2.3.1.1. The 
flasks were induced overnight at 20°C, with 0.25 mM IPTG and harvested as 
described previously (section 2.2.7). A solubility test was performed (sections 
2.2.6.1 and 2.2.6.2) and the pellets lysed and centrifuged (section 2.2.8). 
Purification was then attempted with Ni-NTA chromatography (see 2.2.10), with 




CK600K cells were kindly gifted by Dr Igor Barsukov (University of Liverpool). The 
Rap1 constructs were transformed into these cells after being made competent 
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(section 2.2.5) and glycerol stocks were made, as described in 2.2.3. Further 
cultures were grown of Rap1, as before, with the addition of Kan, due to the 
CK600K cell line having Kanamycin resistance. The cultures were induced with 
0.20 mM IPTG, overnight at 18°C and harvested as described in section 2.2.7. 
Cells were lysed and centrifuged, before being subjected to a solubility test (see 
2.2.6.2). The soluble fraction was purified with Ni-NTA chromatography as 
before. Two potential Rap1 bands were identified via SDS-PAGE, although both 
were in very low yields. The higher molecular weight band was deemed unlikely 
to be Rap1 due to its size. The lower molecular weight band aligned with the His-
Rap1 marker and was an appropriate size. Both were sent to be analysed by mass 
spectrometry. 
Additionally, TEV was added to the fractions eluted from the Ni Column, 
containing the Rap1 targets, to see if an incidence of cleavage could be observed, 
which would indicate the presence of the His-tagged Rap1. These were left at 




The expression trial from section 2.4.2 was repeated, but this time, using a 
mouse Rap1b construct, pre-transformed into CK600K cells (also gifted by Dr Igor 
Barsukov). The cells arrived as a lawn of plated cells, so a scraping was used to 
inoculate 10 ml of LB + ampicillin + kanamycin. These were left overnight, 
incubated and shaking at 37°C. 4 flasks of LB+Amp+Kan were innoculated with 2 
ml of Rap1 overnight culture. These flasks were incubated and shaken at 37°C 
for around 3 hours, until the OD595 reached 0.8. before induction with 0.5 mM 
IPTG overnight at 30°C. Cells were harvested as described in section 2.2.7. 




Cell pellets were lysed and centrifuged as described previously. 1 mM PMSF was 
added after lysis. The construct was untagged and therefore needed to be 
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purified via ion exchange chromatography. The construct comprised of residues 
1-166 and had a theoretical pI of 4.69 according to UniProt. Therefore, the 
protein was run on a Mono-Q column using Q-Buffer A at pH 8, to ensure the 
protein was negatively charged and would bind to the column. 
As the column volume was only 5 ml, and the entire soluble fraction was being 
loaded onto the column, it was theorised that the column may get saturated with 
contaminants, preventing the Rap1b from binding on the first Q-run. This 
phenomenon had been previously observed within the Goult Lab, during previous 
untagged purification studies. In such cases, the protein would be present in the 
flow-through, requiring multiple cycles of Q column until enough contaminants 
had been removed to allow target binding. With this in mind, the cytosol was 
loaded onto the column and the flow through was then run onto the column a 
further four times, and the eluted fractions were taken for each.  
The target was present in the A10-11 fractions of the first run, so these were 
analysed with SDS-PAGE and sent for MALDI Mass Spectrometry analysis. The 
untagged protein needed to be isolated using size exclusion chromatography so 
the A10-11 fractions were pooled and left overnight at 4°C, whilst the 
preparative Superdex S200 gel filtration column equilibrated. The gel filtration 
column had a 5 ml loop, so the sample was concentrated to 5 ml, and loaded 
onto the column. The protein was eluted through the column with the same 
buffer that the protein was already in: Q-Buffer A. 
Fractions from each peak were run across 2 gels, which located Rap1 in the tallest 
peak of the evaluation. The peak showed the protein was purest in fractions E6 




Having optimised the purification protocol for producing pure Rap1, the prep was 
scaled up to 3 litres, so as to obtain enough protein for the NMR experiments.  
Note that 2 mM MgCl2 was added to the buffers used for the Q-column, (Q-buffer-
A and B) in this prep. The first half litre prep was run on the Q column, and the 
fractions analysed with SDS-PAGE. 
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After confirming the proteins presence, in the A10-11 fractions (as in section 
2.4.4.1), it was assumed with reasonable certainty that the results would be the 
same for the remaining five half-litre preps. Each half litre flask of cells was run 
separately on the Q column for ease of isolating the Rap; by loading a higher 
volume onto the column, it risked the Rap failing to bind to the column. 
The 5 remaining Q-columns were run, and in each case, the A10 and A11 fractions 
were collected and pooled with those from the first Q-column run. This resulted 
in around 50 ml of pooled elution. This was concentrated to 5 ml in a 10 kDa 
concentrator and run on the gel filtration column as before. The peak containing 
the proteins fractions were pooled to approximately 8.5 ml and 1 mM PMSF was 
added. The protein was exchanged into phosphate buffer using a pd10 column 
(see 2.2.11.2) prior to undergoing NMR analysis with Rhea. 
 




The Rhea F0-WT and F0-K17E was at a concentration of 39.42 µM in a Shigemi 
NMR tube. The Rap1 was added at a five-fold excess. However, densitrometry of 
the SDS-PAGE bands using ImageJ revealed that it was a four-fold excess, ~160 
µM Rap1. NMR experiments were performed at pH 6.5 and 298K, with a total 











Section 3: Results 
 




Initially, for the first expression trial, both the Rhea F0-WT and F0-K17E were 
predominantly insoluble (Figure 21). In spite of this, the cultures grew well, with 





solubility tests for Rhea F0-WT (A) and Rhea F0-K17E (B). A1/B1 are marker lanes. A2/B2 
represent pre-induction fractions, A3/B3 show post induction +1hr, A4/B4 post 
induction +2hrs, A5/B5 post induction +3hrs/whole cell contents of harvested cells, 
A6/B6 insoluble fraction, A7/B7 soluble fraction. Arrow marks proteins of interest. 
 
Expression levels remained relatively constant from two hours onwards (Lanes 
2-4), with expression appearing to double between the first and second hours. 
Despite good expression, the soluble fraction of each protein was largely void 
of protein, being almost entirely present in the insoluble pellet. It can be 
estimated from the gel that we are looking at upwards of 90% insolubility. It is 
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likely that at these induction conditions, the protein is being made too quickly, 




In the second trial, the expression conditions were adjusted to slow the rate of 
expression, this was achieved by lowering the temperature to 18°C and the IPTG 
concentration to 200 µM. The optimisations resulted in considerably improved 
yields, with the protein being completely soluble (Figure 22).  
 
)LJXUH7ULDOVROXELOLW\WHVWIRU5KHD):7DQG.( 
M is the marker lane. Lanes 1 and 3 show the whole cell fractions for the two sonicated 
pellets of F0-WT, with 2* and 4* showing their soluble fractions respectively. Lanes 5 
and 7 show the whole cell fractions for the two sonicated pellets of F0-K17E, with 6* 
and 8* showing their soluble fractions respectively.  
   
5KHD3XULILFDWLRQ 
 
Having determined the conditions to express soluble Rhea F0-WT and F0-K17E, 
they were successfully purified as evidenced by a large A280 peak observed for 
both proteins (Figure 23A+B). Some of the protein was lost through purification 
due to a leak on the Akta. Fortunately, the protein was abundant, so this lost 







A-B the nickel column evaluations of Rhea F0-WT (A) and Rhea F0-K17E (B) with the main 
peak being displayed between fractions A11-A15 (blue bar). A second peak was observed 
between B15-B14 (red bar), but SDS-PAGE showed it be largely non-specific contaminants 
bound to the column. The peak at A2 (green bar) was due to a leak of high imidazole 
buffer, a technical issue of the Akta system used. C the fractions eluted from the Ni-
column for F0-K17E (F0-WT data not shown). M displays the marker. 1. shows the A2 
fraction, 2. A11, 3. A12, 4. A13, 5. A14, 6. A15. 7. B15, 8. B14, 9. The flow-through.  
 
The proteins were cleaved to remove their His-tags; the results of which can be 








1. F0-WT desalted, before TEV addition, 2. F0-WT + TEV before spin, 3. F0-WT + TEV 
after spin, 4. F0-WT flow-through of Q-column, Arrow (black) shows protein prior to 
cleavage, arrow (red) shows protein after cleavage. 
 
The subsequent round of Q-purification resulted in highly pure Rhea F0-WT, having 






A) A large volume of protein did not bind to the Q-column and was detected in the 
flowthrough. The large peak in A280 absorbance (blue trace) is predominantly F0-WT 
protein. B) shows the evaluation from the Akta for F0-K17E (F0-WT data not shown). A2 
is marked with the green bar and A11-14 with the blue bar. As expected from the  
loading, only a very small peak was observed with most F0 present in the flowthrough. 
B) shows the corresponding fractions from B, where M. Marker, 1. A2, 2. A11, 3. A12, 4. 
A13, 5. A14, 6. The flow-through as shown in A. 
 
The presence of small bands eluted from the Q-column (Figure 25) suggest that 
WKLVSXULILFDWLRQSURFHVVZDVHIIHFWLYHDVD´UHYHUVH4µWKHFRQWDPLQDQWVERXQG




15N labelling is relatively costly, so we wanted to be sure that Rhea could be 
successfully expressed and purified before undergoing this process. Having 
achieved this, the Rhea F0-WT and F0-K17E were labelled with 15N. This was 
achieved using 2M9 minimal media where the sole nitrogen source was 15N-
labelled ammonium sulphate. The solubility tests showed that the optimised 
conditions from section 2.3.1.2 were highly repeatable in this minimal media 





A) 15N F0-WT / B) 15N F0-K17E: M. marker, 1. Whole cell post-induction fraction after 
sonication, 2. Soluble protein fraction after centrifugation, 3. Pooled A11-A15 of Ni 
Column, 4. Desalted protein, 5. Protein after TEV cleavage, 6. Protein after TEV 
cleavage after centrifugation to remove precipitation. Arrow indicates protein location 
prior to cleavage. * marks protein after cleavage C) Ni Evaluation of 15NF0-WT. D) Ni 
Evaluation of 15NF0-K17E. A2 fractions on C) + D) are marked (green bar), as are the 
A11-15 fractions (blue bar) and the contaminant peak (red bar). 
 
When purifying the proteins on the Ni-NTA and Q- columns, they behaved 
identically to when unlabelled. The Reverse-Q process was more dramatic in this 
case, with the contaminants, that were removed by the column, being more 
visible on the gel (Figure 27A+B). The gel also reveals that the additional TEV 
was successful to fully cleave the protein, with a gel being run to clearly 
demonstrate the size difference between the His-tagged and fully cleaved 







A) fractions from Mono-Q for 15NF0-K17E, M. marker, 1. A2, 2. A12, 3. A13, 4. A14, 5. 
B15, 6. Flow-through. B) fractions from Mono-Q for 15NF0-WT, M. marker, 1. A2, 2. A12, 
3. A13, 4. A14, 5. B15, 6. Flow-through (small peak) 7. flow-through (main peak). C) M. 
marker, 1. 15NF0-WT desalted before TEV cleavage, 2-3. 15NF0-WT flow-through 4-5. 
15NF0-WT A2 6. 15NF0-K17E desalted before TEV cleavage, 7. 15NF0-K17E flow-through, 
8. 15NF0-K17E A2. All fractions taken were 50 OERLOHGZLWK Oof sample buffer for 
5 minutes at 95°C. D) Q-Evaluation of Rhea F0-K17E and E) Q-Evaluation of Rhea F0-




Having optimised the conditions to give correctly folded, soluble protein suitable 
for NMR analysis, a doubly labelled 13C 15N protein was successfully produced and 
purified using the same methods (see Figure 28). Uncleaved protein and cleaved 







A) M. marker, 1. Sonicated 13C15NF0-WT pellet, 2. Centrifuged 13C15NF0-WT, 4. A13-A15 
fractions pooled from Ni-Column, 5. Pooled fractions desalted into Q Buffer A, 6. 
13C15NF0-WT after cleavage with TEV before spin, 7. 13C15NF0-WT after cleavage with 
TEV after spin. B) M. marker, 1. 13C15NF0-WT after cleavage with TEV after spin, 2. 
13C15NF0-WT after Ni Resin and additional TEV, 3. 13C15NF0-WT after Ni Resin and 
additional TEV then subsequent spin and filtration, 4. Flow-through of Q column 
showing purified 13C15NF0-WT. C) Evaluation from Ni-Column showing peak between 
A13-A15 fractions (red bar). D) Evaluation from Mono-Q column run, indicating low 
levels of weak binding of contaminants (gel of fractions not shown).  
This protein was used to perform triple resonance NMR experiments for the Rhea 
F0 backbone assignments as described in the Method section 2.3.4.  
Results 3.2: Unlabeled Rhea CD Analysis 
 
CD analyses allowed us to check whether the folding and stability of the wild 
type and mutant Rhea F0 remained the same, to ensure that gross structural 





The top figure shows the circular dichroism full spectrum measurement of Rhea F0-WT 
at 20°C. It confirms that the protein is stable and folded, containing a mixture of alpha 
and beta secondary structure. The main peak is at ~208 nm. The bottom figure shows 
the equivalent full spectrum measurement for the Rhea F0-K17E mutant protein. Both 
measurements are identical, revealing that the mutant protein is similarly folded. These 






Overlaying the full spectrum measurements for Rhea F0-WT and F0-K17E shows that the 
two proteins have identical folding. The ratio of alpha to beta structure is identical 
between both proteins. This allows us to confirm that the K17E substitution has not 
resulted in gross structural changes within the Rhea F0 domain. This is an important 
control for the NMR experiments, as it allows us to conclude that disrupted binding can 
be directly linked to the amino acid substitution, and not therefore as a result of the 
mutant protein being unrecognizable compared to its wild-type counterpart; if the 
changes to the protein are too severe, we would logically not expect binding to occur 





The above figure shows the standard reference spectra for alpha helix (blue), beta sheet 
(orange) and random coil (grey). This data can be compared to the peaks obtained in a 
JLYHQSURWHLQ·V&'VSHFWUXPWRSUHGLFWWKHVHFRQGDU\VWUXFWXUHRIWKHSURWHLQ$ protein 
that is mostly alpha helical for example, will display characteristic peaks at 208- and 222 
nm. The main peak observed in a protein mostly comprised of beta sheet is typically 
around 218 nm, whereas random coil typically peaks at 195 nm. These values are 
idealistic however, and proteins comprised of all three elements will reveal peaks 
somewhere between these values. The full spectrum measurements of Rhea F0-WT and 
F0-K17E for example, indicate the presence of alpha helix (with a negative peak around 
208 nm) and beta sheet (with a second peak occurring at around 215 nm). When 
denaturing the F0 proteins, the measurements at 208 nm clearly demonstrated a shift to 
random coil following denaturation (data not shown).  
 
The CD analysis revealed that the protein contained a combination of alpha and 
beta secondary elements, determined with reference spectra (see Figure 31), in 
good agreement with the structure of mouse F0. An overlay of full spectrum 
measurements of the wild type and mutant Rhea F0 proteins confirm that their 
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folding remains the same via CD (Figure 29, Figure 30), and their thermal 
stabilities are similarly almost identical. The melting curves at 208 nm for each 
protein have the same Tm (midpoint temperature of transition, where 50% of the 
protein molecules are unfolded (Allen and Cooper, 1999)) of 74°C (Figure 32). 
This shows that the mutation of the surface exposed K17 residue has not 
perturbed the structural integrity.  This is an important result as it allows us to 
conclude, with confidence, that the biological phenotype is not due to a 




The top figure shows the denaturation (melting curve) of Rhea F0-WT (green) and F0-
K17E (orange) from 20°C to 90°C, at 208 nm. The melting curve for both proteins is 
identical and reveal a Tm (midpoint temperature of transition, where 50% of the protein 
molecules are unfolded (Allen and Cooper, 1999) of 74°C (calculation of which is shown 
in the bottom figure). This shows that the mutation of the surface exposed K17 residue 
has not perturbed the structural integrity.   
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Results 3.3: 15N Rhea NMR Analysis 
 
Having successfully purified the 15N labelled protein, 1D and HSQC NMR spectra 
were obtained for each. Both spectra show that the proteins were correctly 
folded, with the HSQC displaying evenly dispersed peaks (Figure 33), and the 1D 
spectra displaying shifted methyls, indicative of a folded monomeric protein. 
Overlaying the spectra confirmed that we indeed had isolated the wild type and 
mutant versions of the same proteins, with a heavy degree of overlap of the 
peaks of the two spectra but small scattered differences between them. 
 
)LJXUH+64&DQG'VSHFWUDRI5KHD):7DQG).( 
Wild-Type (A) and Mutant (B) Rhea F0 HSQC spectra. Wild-Type (C) and Mutant (D) Rhea 
F0 1D spectra and overlay (E). The spectra of Rhea F0-K17E and F0-WT show that the 
proteins were correctly folded, with the HSQC displaying evenly dispersed peaks. The 
1D spectra displayed shifted methyls, indicative of a folded monomeric protein. 
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Overlaying the spectra confirmed that we indeed had isolated the wild type and mutant 
versions of the same proteins, with a heavy degree of overlap of the peaks of the two 
spectra but small scattered differences between them. 
   
Results 3.4: Rhea Backbone Assignment 
 
The assignment of Rhea F0 was successfully completed (Figure 34) with all amide 
peaks being assigned as well as the CA, CB and CO resonances for each residue, 
the only missing assignments were the CO immediately before proline residues. 
As explained in the methods, this is due to proline residues not having an amide 
and therefore not having their own spin system. The Rhea F0 domain contains 
three prolines, which were therefore not assigned. For a detailed breakdown of 







A completed section of the assignment is shown below (Figure 35). 
 
   
)LJXUH&RPSOHWHG$VVLJQPHQW6WULSVIURP&&3105IRU5KHD) 
The location of 4 assigned sequential amino acids on the HSQC spectra (A) and their 
corresponding strips (B), showing the HNCACB and HN(CO)CACB. The HNCACB shows the 
alpha and beta carbons of each amino acid, in addition to the alpha and beta carbons 
of the residue at i-1 in the N terminal direction. The alpha and beta carbon chemical 
shifts of 69 are diagnostic of a threonine. The arginine next to it was harder to assign 
with certainty, however, it is next to a glycine; clear from not having a beta carbon 
and a characteristic alpha position. The sequence G-R-T only appears once in the amino 
acid sequence, meaning that we can assign these residues with certainty. Further 
certainty comes from there being a proline at the next residue downstream of 67G. 
Proline do not have an amide and so do not produce a spin system, and as expected, 
there is no matching alpha and beta for the alpha- and beta-1 chemical shifts observed 
in the 67G HNCACB. This method allows us to assign the entire spectrum.     
 
Having completed the assignment, the chemical shifts of all the CA, CO and CB 
residues were assigned to their corresponding residues, completing the backbone 
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assignment. These assignments were then exported in NMRSTAR format and 
deposited into the Biomagnetic Resonance Bank (BMRB), a public repository for 
NMR data.  
As well as providing sequential information, the chemical shift assignments were 
used to calculate the dihedral angles based on chemical shift indexing with the 
program DANGLE which forms part of the CCPNMR package. This created a 
Ramachandran Plot output and determined the secondary structure elements of 
the F0 domain (Figure 36 left). By comparing these to a predicted structural 
model created using Phyre, which used mouse talin F0 as a template, we could 
confirm that the assignments were correct and also confirm that Rhea F0 has the 
same secondary structure elements as mouse talin F0 (Figure 36 right). These 






The Ramachandran Plot predicted sheet structure between residues 16-21 (A) and a helix 
between residues 28-36 (B) which maps accurately to corresponding regions of the Phyre model 
(right) (Kelley LA et al. 2015). 
 




Full length Drosophila Ras-like Protein 3 was found to be insoluble in BL21(DE3) 
E.coli cells. The cells were very slow to grow, suggesting that the constructs were 
inducing toxicity within the cells. Additionally, the thawed cell pellets were very 
stringy, suggesting the presence of a large amount of DNA. It appears that the 
tagged construct expressed better, however both constructs were insoluble 
(Figure 37A). Sonicating the cells in a larger volume was attempted, to test 
whether ineffective sonication had resulted in the protein being in the insoluble 
debris pellet (Figure 37B). The protein appeared to remain insoluble. Due to their 
overexpression, the proteins were easily identifiable on the gel, with their bands 
appearing at the expected size of around 20kDa. The untagged construct was also 





A) M. marker, 1. Pre-induction His-Rap1, 2. Whole cell fraction for His-Rap1 (also shown 
in B1), 3. Insoluble fraction of His-Rap1, 4. Soluble fraction of His-Rap1 (also shown in 
B2), 5. Pre-induction UT-Rap1, 6. Whole cell fraction for UT-Rap1 (also shown in B3), 
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7. Insoluble fraction of UT-Rap1, 8. Soluble fraction of UT-Rap1 (also shown in B4). His-
Rap1 is indicated with the green box, UT-Rap1 with the blue box.  
 
Attempting to purify the soluble fraction of the His-tagged construct was 
unsuccessful, despite an initially promising A280 peak being observed in the Ni-
NTA purification process (Figure 38). 
 
)LJXUH$WWHPSWLQJWRSXULI\5DSIURP%/'(FHOOV 
A) evaluation for the His-Rap1 soluble fraction. A280 is shown in green and A260 in red. 
The green bar indicates the location of A2, the Blue bar indicates A11-B14 B) Fractions 
from Q evaluation. M. marker, 1. A2, 2. A11, 3. A12, 4. A13, 5. A14, 6. A15, 7. B15, 8. 
B14, 9. Flow-through. The only possible target is highlighted with the blue box, 
however, it was determined to be slightly too large and at too low a yield for 
meaningful assay.  
 
The peak at A280nm was re-examined and shown to also have high absorbance 
at A260nm, suggesting that the peak could be the result of a large amount of 
DNA. This idea is supported by the consistency of the pellets upon thawing, and 
the slow cell growth rate observed. There was a potential target identified from 
the gel as being the Rap1 protein (blue box, Figure 38B), however, it was in too 
low a yield for use in the NMR experiments. Additionally, the identified target 






We were gifted CK600K cells by Dr Igor Barsukov (University of Liverpool), who 
has expertise in working with small GTPases. These cells were more tolerable of 
the Rap1 vectors than BL21(DE3) cells, due to a faster growth rate. The results 
of this expression test was similarly disappointing however, with there being no 




solubility test of drosophila Rap1-His (1 + 2) and Rap1-UT (3 + 4). M. marker, 1/3. whole 
cell fractions, 2/4. soluble fractions 
 
The gel did reveal several proteins at approximately the right size of the Rap1 
tagged construct, however, these proteins were the same size across both the 
tagged and untagged construct lanes, suggesting that they were not the Rap 
protein. In order to look for the presence of any Rap1, even if at low expression, 
the soluble fraction of the His-tagged construct prep was purified with Ni-NTA 






A) Ni Evaluation of His-Rap1 in CK600K cells displaying a small double peak (400 mAU) 
between the A12 and A14 eluted fractions. The green bar indicates A3, the blue 
indicates A11-A15 and the red indicates A12-14 B) fractions from Ni column elution. M. 
marker, 1. A3, 2. A11, 3. A12, 4. A13, 5. A14, 6. A15, 7. flow-through, 8. Sonicated His-
Rap1 from 3.1.5 prep. Green box indicates a potential (but unlikely) target for Rap1, 
the red box indicates a more likely candidate for Rap1 (despite low yield), the blue box 
indicates the presence of His-Rap1 (used as a marker). Green and red targets were 
analysed with mass spec.  
 
The results were again disappointing, with only a small peak being observed on 
the evaluation. Two possible candidates were identified that could have been 




TEV addition to the A12-14 elutions from the Ni-Column; no cleavage was observed. M. 
marker, 1. A12 before TEV addition, 2. A12 after TEV addition, 3. A13 before TEV 





No cleavage was achieved with these proteins (Figure 41), making it likely that 
neither targets were Rap1. To confirm this, stabs of the gel (shown in Figure 40B) 
were taken and identified as E. coli 30S ribosomal protein S2 and cAMP-activated 
global transcriptional regulator CRP (Figure 42), via Mass Spectroscopy, 






Upper the mass spec of the higher molecular weight target was identified as E. coli 30S 
ribosomal protein S2 and lower the mass spec of the lower molecular weight target was 
identified as E. coli cAMP-activated global transcriptional regulator CRP, with a high 




It was observed in the literature that most structures of Rap1b had previously 
been based off a truncated protein (residues 1-166, spanning the conserved G-
Domain), in CK600K cells, using a ptac expression system ((Edreira et al., 2009), 
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(Kupzig et al., 2006), (Tucker et al 1986)). Dr Igor Barsukov (University of 
Liverpool) gifted us this construct, which was originally supplied to Dr David 
Critchley, by Dr Alfred Wittinghofer at the Max Planck Institute of Physiology; a 
leading expert in the structural analysis of small GTPases.  
The resulting expression and solubility test from this construct was promising 




M. marker, 1. Pre-induction, 2. Post-LQGXFWLRQ´ZKROHFHOOµ3RVW-induction insoluble, 
4. Post-induction soluble. Fractions were loaded to adjust for pre- and post-induction 
ODs (10.4µl or pre-induction and 4.5µl of post induction fractions). The blue box 
indicates the mouse Rap1b location. 
 
The truncated Rap1b is around 2kDa smaller than the full length protein, as 
determined by UniProt, with a molecular weight of 18 kDa. At this size, there 




As the construct was untagged, purification was successfully achieved using Q-






A) Q-Evaluation of first cycle of Q indicating presence of large volumes of protein. A10-
B14 is indicated by the blue bar B) Flow through of first round was loaded onto Q-
column again. The evaluation is shown. The green bar indicates A2 and the red bar 
indicates A10-B15. Significantly less protein eluted from the column at the lower part 
of the salt gradient. A large amount of protein remained bound to the column until the 
high part of the salt gradient washed through the column. Data for successive runs are 
not shown. C) gel fractions from across peak of first Q-cycle. M. marker, 1. A10, 2. A11, 
3. A12, 4. A13, 5. A14, 6. A15, 7. B15, 8. B14, 9. Flow-through. D) M. marker, 1. A2, 2. 
A10, 3. A11, 4. A12, 5. A13, 6. A14, 7. B15, 8. Flow through from first round, 9. Flow 
through from second round. The blue box indicates the location of Rap1b. 
 
It was found that the target protein bound to the column in the first round of Q-
Purification (Figure 45A+C). This protein was concentrated down to 5 ml and 







A) gel filtration evaluation of the pooled A10 and A11 fractions from the Q-column. C1 
was taken from the region indicated by the green bar, the dark blue bar indicates D2-
D4, the light blue D7-D12 and the red E4-E11. The red box indicates the Rap1 peak.  B) 
and C) fractions taken from peaks across the evaluation to identify Rap. M. marker, 1. 
C1, 2. D2, 3. D3, 4. D4, 5. D7, 6. D10, 7. D11, 8. D12, 9. E2, 10. E7, 11. E8, 12, E9. D) 
running the Rap1 peak 1. A11 fraction from Q column 2. E4, 3. E5, 4. E6, 5. E7, 6. E8, 
7. E9, 8. E10, 9. E11.  
 
Gel filtration was successful in isolating pure Rap1b (Figure 45). An interesting 
observation is that the isolated protein was present in two bands on the gel.  
Both of these bands were sent for Mass Spec analysis and the results confirmed 
that they were both Rap1b (Figure 46). It is possible that the two bands on the 
gel represent the nucleotide-bound state of the protein, with one band 
representing the GDP bound form, and the other the GTP bound form. 
Alternatively, one band could represent both GTP and GDP forms, with the other 







Mass Spec analysis of the top band of the gel (Figure 44C) shown (top) and of the lower 
band of the gel (Figure 44C) shown (bottom). Both evaluations indicate that the Rap1b 










Having optimised the purification protocol, the procedure was scaled up to 3 
litres, to produce sufficient Rap1b for NMR analysis. The results of the scaled up 
experiment reveal that the Rap1 Q-Purification was comparable to in section 
3.5.4.1, as shown by the A10-11 fractions eluted from the first half litre prep 
(see Figure 47 lanes 1 and 2).  
 
)LJXUH)UDFWLRQVIURPWKH,RQ([FKDQJHSXULILFDWLRQRI5DS 
Q-fractions from across peak of first ½ L prep. M. marker, 1. A10, 2. A11, 3. A12, 4. 
A13, 5. A14, 6. A15, 7. B15, 8. B14, 9. Flow-through. Blue box indicated the location of 
Rap1. 
 
It should be expected that the intensity of Rap1 seen on a gel should be 
approximately the same, in the pooled A10-11 fractions from all 6 half litre preps, 
as for the A10-11 of the first 500 ml prep. As seen below (Figure 48 lane 1), the 
Rap1 intensity appears to have the same intensity as in the first 500 ml prep 
(Figure 47 lanes 1 and 2).      
After pooling the six A10-11 fractions and concentrating to 5 ml, a large excess of 
Rap1b was observed (Figure 48 right, lane 2). In spite of this, the Rap1 that eluted 
from the gel filtration column was at a lower yield than expected; the peak 
indicated a yield of protein approximately the same, if not slightly less than the 
amount observed during the optimization process (Figure 45). Nevertheless, the 
peak was run on a gel and shown to be pure (Figure 48 right, lanes 3-8). The exact 
reasons for this loss on the gel filtration are not clear but one possible explanation 






left: gel filtration evaluation zoomed on the Rap1 peak between fractions E4-E9. Right: 
gel filtration fractions M. marker, 1. the pooled A10-A11 fractions from the 6Q rounds, 
2. Fraction 1 after concentrating to 5 ml, 3. E4, 4. E5, 5. E6, 6. E7, 7. E8, 8. E9. 
 
Results 3.6: Rhea/Rap1 NMR Experiments  
 
Having purified the Rap1 protein, Rhea F0-WT and F0-K17E, NMR was used to look 
at the binding of Rap1 to labelled Rhea. The NMR experiments showed that Rhea 
F0-WT was able to bind to the Rap1 protein (Figure 49, Figure 50, Figure 53, 
Figure 54), with significant shifts being observed. The F0-K17E protein however, 
was unable to bind the Rap1 protein, despite Rap1 being in high excess (Figure 
51, Figure 52, Figure 53, Figure 54).  
Having assigned the peaks in the HSQC spectra (section 3.4) it was possible to 
identify the residues that the peaks that shifted were. To do this chemical shift 
mapping was used. This is the process of colouring chemical shifts onto the 
surface of a protein structure, in order to determine where a binding site lies. 
By colour coding the mapping according to the size of the shift difference, the 
key residues involved in binding are highlighted on the structure.  5 residues had 
particularly large chemical shifts, which mapped to the end of the F0-WT domain 
(Figure 54, Figure 55, Figure 56), revealing the Rap1 binding surface on Rhea F0. 
These shifts were localized around the K17 location, with V15 and T18 being in 
close proximity in the amino acid sequence. Two of the other shifts, K37 and E40, 
are close to the K17 in tertiary structure. The final shift at Q9 is likely to be a 
  
81 
secondary consequence of the shift caused in T18, which is in close proximity to 





















Top, the K17E spectra and Bottom, the K17E spectra on its own (blue) and in the 
















































Model for the predicted binding of Rap1 (dark grey) to talin F0 domain (light grey). The 
residues that displayed the largest shifts in the Rhea F0 have been coloured onto the 
mouse talin F0. This was done by sequence alignment of Rhea and Talin. The Rap1 
switch 1 domain has been coloured in cyan, and the F0 K17 in dark blue. The side 
chain structure for K37 has been shown due to its close proximity to the switch domain 
of Rap1. The drosophila shifts (Figure 55) are coloured onto this mouse model using 
sequence alignments between the mouse and drosophila talin F0 (Figure 58). The 







As a control, after running the NMR experiments, a gel was run with a fraction 
from each Shigemi NMR tube, to determine the concentration of Rap1 used in the 
experiments, as well as to ensure that the ratios of both Rhea and Rap1 were 
identical in each experiment. As shown in (Figure 57), the proteins were all added 
at identical ratios. Despite aiming for a 5x excess of Rap1 to Rhea, it was 





Gel of the NMR experiments determining if Rhea F0-WT bound to Rap1 (lane 1), and if 
the Rhea F0-K17E bound to the Rap1 (lane 2). The Rap1 was added in ~4x excess to the 
Rhea as measured from the band density using ImageJ (Schneider, Rasband and 




The Fly Rhea F0 sequence is shown (top) with the mouse Talin F0 sequence aligned 
(bottom). Green residues are identical, red are different and yellow are similar amino 




Section 4: Conclusions 
 
4.1 Summary  
 
In this study, a direct interaction between Rap1 and Rhea, the fly homolog of 
talin, has been demonstrated for the first time. Biochemical and biophysical 
characterisation have allowed us to map the Rap1 binding site on Rhea, and 
confirm that a K17E substitution, on Rhea, completely abolishes Rap1 binding. 
These findings have strong implications for RIAM-independent integrin activation, 
that could change our understanding of focal adhesion formation.   
Over the course of this study, optimal conditions to express and purify Rhea F0-
WT and the F0-K17E mutant have been elucidated. After optimisation, both 
proteins express well in E.coli BL21(DE3) cells and are efficiently purified by Ni-
NTA based affinity chromatography. For both the wild-type and mutant protein, 
maximum yields of ~50-60 mg/litre were obtained. It was confirmed with circular 
dichroism that the full spectrum measurements, of the wild-type and mutant Rhea 
F0, were identical, as were their Tm values. This confirms that substitution of the 
K17 residue did not interfere with structural integrity, which was supported by 
the NMR data.  
Optimal Rap1 protein was achieved using the mouse Rap1b 1-166 truncated 
construct, in CK600K cells, missing its hyper-variable C-terminal region. This 
region is highly conserved to that in fly (90% identical). It was demonstrated using 
NMR, for the first time, that the drosophila Rhea F0 domain is able to bind to 
Rap1b. By mutating a single basic lysine 17 residue, to an acidic glutamic acid 
residue, with a K17E mutant, the Rhea F0 protein is no longer able to bind to 
Rap1b, even when a four-fold excess of Rap1b is present. Triple resonance NMR 
experiments enabled the chemical shift changes upon Rap1b binding to be mapped 
and revealed the location of the Rap1b binding site on the wild-type Rhea F0. The 
largest chemical shift changes were observed for V15, K17, T18, K37 and E40, 
which are in the centre of this binding surface. To support these findings we 
generated Structural models of Rap1:Rhea F0. These structural models of 
Rap1:Rhea F0 binding agree with our findings, and these residues with the largest 
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shifts all are seen to make close contact with the Rap1, and confirms that Rhea 
interacts within close proximity of the Switch I domain of Rap1.  
Together this work confirms that the fly talin, Rhea, can form a direct interaction 
with Rap1b and that a K17E mutant abrogates this interaction. The K17E mutant 
has been shown to cause lethality in flies and this work provides biochemical 




The biochemical data from this study will contribute towards a paper including 
work from our collaboration with Guy Tanentzapf, at the University of British 
Columbia, Vancouver, who has demonstrated that the Rhea K17E mutation is 
embryonic lethal in drosophila. These experiments are being performed using 
CRISPR insertion of the mutant into the endogenous talin gene. The observed 
phenotypes of these non-viable embryos, in addition to the embryonic stage at 
which death occurs, will allow further conclusions to be drawn about the nature 
of the mutation. Strengthening the evidence from the embryology data, will be 
experiments to attempt recovery of the Rhea mutant phenotype. If the K17E 
mutant can kill a fly embryo, then a rescue with the functional, wild-type protein 
will confirm that the observed phenotype is a direct consequence of the mutation.  
Our structural work has proposed a biochemical explanation for the observed 
phenotypes: Rhea K17E is unable to bind to the Rap1 protein and this interaction 
could be key to embryonic viability.  It is already known that drosophila Rap1 
deletion mutants are unable to survive to adulthood, with migration defects 
observed during gastrulation (a time of extensive reorganisation in the early 
embryo, giving rise to the three germ layers) (Asha et al., 1999). It will be 
interesting to compare the phenotypes of Rap1 deletion mutants to those seen 
with the K17E mutants. Observing defects in cell migration, cell shape, or ovary 
and eye disk morphogenesis (Asha et al., 1999) will heavily implicate Rap1 
involvement in the lethality resulting from the Rhea K17E mutation.  
Rap1 evidently has other roles in the cell, including cell-cell junction formation 
(Knox, 2002), which will likely contribute to phenotypes observed in Rap1 deletion 
mutants. We would therefore expect that some of the Rap1 deletion phenotypes 
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would not be observed, if purely targeting the Rap1:Rhea pathway. What is 
currently unknown is how this pathway links to the classic pathway of integrin 
activation through Rap1 dependent recruitment of talin via RIAM (6KDWWLO.LPDQG
*LQVEHUJGoult et al., 2013). If the embryonic lethal phenotype is a result 
of interaction between Rap1 and Rhea, then the classic pathway is unable to 
recover or compensate for the lack of this interaction. This could lead to 
implications that the adhesion is double-dependent on Rap1, both through the 
classical pathway, whereby RIAM serves as an intermediary and also directly 
through the FERM domain. Further study will be required to fully understand the 
relative roles, and interplay between, these different pathways and at which stage 
each one is most important. One way to explore this, might be with carefully 
designed deletion and substitution mutants of talin, RIAM and Rap1 in embryos.  
Interestingly, it is already shown that the F0 domain is required for integrin 
activation in a context dependent manner. Bouaouina et al (2008) show that talin 
)DORQH FDQDFWLYDWHş LQWHJULQV EXW IDLOV WR DFWLYDWHş LQWHJULQV 7KLVZDV
despite the fact that the F3 domain bound both integrins with similar affinity. 
Their key finding, perhaps relating to Rap, is that larger fragments of the FERM 
domain, containing F0, are able to activate the beta1 integrins. Their proposal is 
that the F0 domain could be key for orientating the talin protein, by some as of 
yet unknown mechanism, in a way that allows integrin activation. This experiment 
shows us that there are key processes occurring that are poorly understood and 
more complex than our current understanding. The data in this report coupled 
with the findings of Bouaouina et al, allows us to propose a model whereby Rap1 
is involved in orientating the talin molecule, in distinct integrin contexts. It would 
be interesting to design experiments to observe how the FERM domain interacts 
with integrin, following the K17E substitution. It could be that the F3 domain binds 
to specific beta-integrin tails, but requires Rap1 to anchor correctly to the 







The possibility of Rap1 binding to talin was first proposed and demonstrated by 
Goult et al in 2010. Sequence alignments of the Rhea F0 domain were shown to 
have two distinct regions of conservation; on opposite faces of the F0 domain. The 
first region defines the F0-F1 interface, whereas the second was observed to be 
similar to the RalGDS RA (Ras-associating) site (Huang et al, 1998); RalGDS is a 
structural homolog of the talin F0 domain. One question that arose from the 
discovery of this talin RA site, related to the possibility of Rap1 binding being non-
specific; i.e. could other GTPases bind to the site. Goult et al (2010) took one of 
the closest-related protein to Rap1 (H-Ras) and demonstrated that it fails to bind 
to the F0 domain. Interestingly however, the membrane targeting sequences of 
various Ras isoforms (H, K, R and N) have been able to increase integrin activation 
via RIAM (Lee et al., 2008). This suggests further roles for the GTPases in focal 
adhesion assembly and warrants further investigation; particularly when we 
consider the fact that a single amino acid substitution can abolish Rap1 binding, 
leaving the possibility of other GTPases binding to the Rhea RA site.  
Another consideration comes from studies of RIAM function in platelets. A 
fascinating study (reviewed: Plow and Qin, 2015) has investigated the previous 
conceptions that RIAM is crucial for integrin activation in platelets. The findings 
reveal that RIAM-null mice, created through homologous recombination, exhibit 
normal integrin function and activation (Stritt et al., 2014). The authors did 
controls to test that RIAM was not present in the RIAM-deletion cells, and 
GHPRQVWUDWHG WKDW SODWHOHW DJJUHJDWLRQ GHSHQGHQW RQ Ş,,Eş LQWHJULQ ZDV
identical in the wild-type and mutant cells. They also used antibodies, that 
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selectively bind to integrin in its active form, to show that levels of integrin 
activation were also identical in the RIAM deficient mice. The implications for this 
study ² that platelets do not require RIAM for normal integrin function ² are 
profound: in some cell types, the classic integrin activation pathway does not 
apply. This in turn means that integrin must be activated through other pathways, 
which adds weight to our argument that Rap1 could be involved in a similar 
process, through direct interaction with the Rhea FERM domain. It would be 
interesting to take this RIAM-null model, where integrin activation is unaffected, 
and design studies to further asses the role of Rap1 and Rhea in this context. It 
would be expected that a K17E version of talin in these models might result in 
complete loss of adhesion as both Rap1 dependent routes would be knocked out. 
It is my opinion that we may be able to best understand these complex protein 
interactions, when specific pathways can be selectively switched off, potentially 
making platelets a vital platform from which to study integrin activation. Platelets 
however, are difficult to generate and manipulate, arising from a complex 
megakaryocyte maturation process in vivo (Thon and Italiano, 2010). These 
findings do not rule out the possibility that there are other proteins able to 
perform the role of RIAM in platelets, so extensive study would be required. 
Additional interest comes from Pico- (the fly homolog of RIAM) deletion mutants, 
which have no strong phenotype in the embryo according to internal discussions 
with our collaborators. This again suggests RIAM-independent integrin activation. 
This is controversial however, with more sever Pico-deletion phenotypes being 
reported by some (Lyulcheva et al., 2008).    
 
4.3 Further Work 
 
There is much work to be done which directly continues from our current progress. 
Firstly, in collaboration with Marie Anderson in the Goult Lab, crystallography 






Crystals of Rap1b:Talin2 (arrow) have already been prepared in collaboration with Marie 
Anderson. These structures have yet to be solved, as of writing. Crystals can be seen 
growing in the phase separation. 
 
Crystal structures of the Rhea FERM domain and fly Rap1 homolog would further 
our understanding of how these interactions are occurring. With more time, NMR 
titration experiments would have been performed to allow us to quantitate the 
binding of Rap1 and Rhea and calculate the binding constants. This would have 
been performed by repeating the NMR shift experiments, but using a range of 
increasing Rap1b concentrations.  
Work also needs to be done on determining the cause of the double band of Rap1b 
observed during purification (see Figure 48). An initial thought was that 
translational errors or protein cleavage could be forming two versions of Rap1. 
The Mass Spectroscopy data however, encompassed fragments from across the 
same regions of the Rap protein in each band. Unless the cleavage is occurring at 
the N terminus, it can be concluded that this is not occurring. More likely, is the 
possibility that the distinct bands represent the nucleotide-bound state of the 
protein. It is possible that one band could represent the GTP/GDP bound state, 
and the other the apo form. Alternatively, one band could represent the GTP 
bound state, and the other the GDP bound state. Based on the fact that a source 
of external GTP was not supplied to the E.coli, it seems more likely that the Rap1 
protein pool fails to reach saturation in the cell, and therefore we have some 
protein present in the apo form. Additionally, the Rap1 has intrinsic GTPase 
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activity, which could have converted all GTP to GDP by the time the protein was 
purified. This leads to an extension of work where the intrinsic rate of GTP 
hydrolysis is studied in Rap1. This could be extended further by measuring how 
these rates change in the presence or absence of different GAPs and GEFs. An 
important optimisation to the experiments would be to purify the protein and strip 
out any GTP/GDP with EDTA and then supply an external source to saturation. To 
overcome the intrinsic hydrolysis, a non-hydrolysable GTP analogue (such as GNP-
pnp) could be used in subsequent experiments. The process of nucleotide 
exchange has been documented previously (Gorzalczany et al., 2000). This would 
likely resolve the double-band issue, and would allow us to more accurately assay 
the differences, between the active and inactive forms of Rap1, in Rhea binding.    
To strengthen our data, we could perform experiments that show that the Rhea 
F0-K17E mutation does not affect integrin binding. This would involve expressing 
the entire FERM domain and measuring its binding constant for integrin, and then 
repeating this with the K17E mutation present. My current theory however, is that 
the F0 domain is far away enough from the F3 domain, and FERM membrane 
binding residues, to have little effect on integrin binding. Additionally, 
experiments performed by Dr Goult have shown that integrin binding can still 
occur when labelling different FERM domains with (GST); a large 25 kDa affinity 
tag.    
Another series of experiments that could be performed, are substitutions of 
different amino acids on Rhea F0. Then we could assess the ability of the protein 
to bind to Rap1 again. Interestingly, K37 on Rhea is in close proximity with the key 
switch I domain of Rap1 (see Figure 56, Figure 62A); it can therefore be predicted 
that a substitution of this amino acid would drastically affect the ability of Rap1 
to bind. Interestingly, K37 is one of the key residues that displayed a large shift 
on the Rhea F0-WT when in the presence of Rap1. Dr Goult has already performed 
this experiment with the mouse talin F0, by substituting R35 (the conserved K37 
residue in Rhea (see Figure 58) for glutamate, and shown that this abolishes Rap1 
binding (Unpublished results).  We could also approach this experiment from the 
opposite angle and perform triple resonance experiments on Rap1, allowing us to 
map the Rhea F0-WT induced chemical shifts. This would allow us to identify 
potential targets on the Rap1, to mutate, that would prevent Rhea binding. A 
limitation with this experiment however, would be that Rap1 likely has a larger 
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number of binding partners and downstream effectors, making embryological 
studies more difficult to interpret.    
Further cell biology and embryology experiments could investigate subcellular 
localisation of Rhea and Rap1, and particular cell types, to explore if this pathway 
can be specifically isolated from the RIAM pathway. Likewise, if mutations can be 
identified that disrupt the RIAM binding site on talin they could be used to tease 
apart these two different pathways. This could conclude if these interactions are 
occurring in the membrane, at focal adhesions, or in the cytosol.      
Ideally, there is a desire to complete the optimisation of the true drosophila Ras-
like protein 3 (the Rap1b homolog), which should prove straight forwards following 
the optimisation of the mouse construct. However, sequence alignments of 
residues 1-166 of mouse Rap1b with the corresponding region of drosophila Ras-
like protein 3, show 90% identity between the proteins, with most changes being 
semi-conserved (see Figure 61). Additionally, the main differences between the 




The mouse Rap1b sequence is shown (top) with the drosophila Ras-like protein 3 sequence 
aligned (bottom). Green residues are identical, red are different and yellow are semi-
conserved amino acids (i.e. substitution of polar to polar, basic to basic etc.) (Altschul et 












A) Rap1 is coloured in dark grey with the structural differences between it and Ras-like 
Protein 3 being shown with red spheres. The switch I domain is shown in light blue. 
Rhea F0 is shown in light grey. 
B) For clarity, the mesh surface of Rap1 is shown, to illustrate the spatial separation of 
Rap1 and Ras-like protein 3 differences.   
 
Another potential area for study, is the comparison between the binding of Rap1b 
to the F0 domains of Talin1, Talin2 and Rhea Isoform B.  Interestingly, the mouse 
talin1 F0 domain comprises 85 amino acids. Mouse talin2 and Rhea Isoform B 
however, each have 87 amino acids. The F0 domains of mouse talin1 and mouse 
talin2 share 76% identity. The F0 domains of mouse talin1 and Rhea Isoform B 
share 51% identity, compared to the 56% identity between talin2 and Rhea. These 
two additional amino acids (at position 10-11), present (but not conserved) in both 
talin2 and Rhea Isoform B, could have a profound effect on the binding affinity of 
these two proteins, to Rap1b, when compared to talin1. This is a question that 
the lab has begun to answer: could the interaction between Rap1 and talin2 have 
tighter affinity and thus could a direct interaction with Rap1 play a larger role in 
talin2 function? 
 
Our current studies have created a robust pipeline for the expression and 
purification of Rap1 and further work needs to be done to extend this progress to 
other GTPases. Work began on expressing Rab25, a more distant relative of Rap1, 
which belongs to the Rab sub-family of Ras GTPases. The intention was to study 
the Rab25 in the context of its ability to bind to the beta1 cytoplasmic tails of 
alpha5beta1 integrins, in order to understand its role in integrin recycling 
pathways. This interaction was first discovered by Caswell et al in 2007. Due to 
time constraints, this study remain unfinished, but the data obtained was very 
promising; it was found that full length His- and GST-tagged Rab25 constructs 
(with pet15b and pGEX4TI expression systems respectively), were largely insoluble 
in BL21(DE3) E.coli cells. This is in spite of high levels of overexpression (Figure 
63). The Rab25-GST construct had a marginal soluble fraction, with which some 
preliminary pulldown experiments were performed with beta1 integrin (not 
VKRZQ 7KHVH UHVXOWV DSSHDUHG WR FRQILUP &DVZHOO·V ILQGLQJV WKDW 5DE DQG
beta1 integrin bind, but due to time constraints were not confirmed with 






M, Marker, 1. Pre-Induction, 2. Post-induction Whole Cell, 3. Insoluble Fraction, 4. Soluble 
fraction. Rab25-GST location is shown in red, a small amount of soluble protein is 
indicated by the red arrow. Rab25-His location is shown in green. 
 
By extending our findings from Rap1, the next step in this process would be to use 
an untagged construct of Rab25, missing the hypervariable C-terminal domain, in 
the CK600K cell line with similar induction conditions and expression systems.  
To conclude, many aspects of focal adhesion complex formation, and integrin 
activation, are poorly understood, despite significant progress in these areas of 
research. It is likely that there are many new interactions that are yet to be 
documented, that could completely change our understanding of these processes. 
The currently described pathways also need much further study to truly 
understand, and allow us to apply this knowledge for therapeutic gain. With cell 
migration being so key to development and invasive cancer, this is an area of 
critical importance for research. The findings of our study shows that this novel 
Rap1b:Rhea interaction is evidently essential for adhesion, the implications of 
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